cancer drugs

sheet music wrong note
Biotech

Prelude calls it curtains on lead SMARCA2 cancer asset

The biotech is directing energy toward another SMARCA2 degrader, its sole remaining clinical-stage asset.
Darren Incorvaia Aug 14, 2025 10:44am
Person throwing piece of paper into full waste bin

Gilead culls last MASH program, 2 cancer assets

Aug 8, 2025 11:50am
Paint brushes sitting on a colorful canvas

Radiopharma biotech Artbio paints path to clinic with $132M

Jul 29, 2025 7:30am
Hiker having trouble climbing mountain

Processa hands cancer drug back to Opus over time, cost involved

Jul 1, 2025 11:12am
Y chromosomes

‘New realm of biology’: missing Y chromosomes worsen cancer

Jun 6, 2025 1:12pm
Close-up of panning for gold

Astellas aims for CLDN18.2 gold with $1.34B licensing deal

May 29, 2025 7:30pm